A thrombus in the left atrial appendage (LAA) has been considered to be a contraindication
to percutaneous LAA closure.
1
Its persistence despite antithrombotic therapy (AT) or contraindication to oral anticoagulant
is a challenging situation because there is no alternative for reducing the high embolic
risk.Glikson M, Wolff R, Hindricks G, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion [e-pub ahead of print]. Europace https://doi.org/10.1093/europace/euz258.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
Glikson M, Wolff R, Hindricks G, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion [e-pub ahead of print]. Europace https://doi.org/10.1093/europace/euz258.
- Percutaneous left atrial appendage occlusion in patients with atrial fibrillation and left appendage thrombus: feasibility, safety and clinical efficacy.EuroIntervention. 2018; 13: 1595-1602
- First-in-man percutaneous LAA closure with an amplatzer amulet and triguard embolic protection device in a patient with LAA thrombus.J Invasive Cardiol. 2017; 29: E51-E52
Article info
Publication history
Published online: January 16, 2020
Accepted:
December 31,
2019
Received:
October 1,
2019
Footnotes
See page 968.e5 for disclosure information.
Identification
Copyright
© 2020 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
